Guillain-Barre syndrome in 220 patients with COVID-19

Finsterer, Josef; Scorza, Fúlvio A.

doi:10.1186/s41983-021-00310-7

Cited by 103 publications

(117 citation statements)

References 11 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Altogether, 105 articles about SARS-CoV-2-associated neuropathy describing 220 patients with Guillain-Barré syndrome (GBS) 4 and 41 patients with non-GBS neuropathy were retrieved 5,6,7,8,9,10,11,12,13,14 . The age of these 261 patients, reported in 244 of them, ranged from 8 to 94 years.…”

Section: Resultsmentioning

confidence: 99%

Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit

Finsterer

Scorza

et al. 2021

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

Background: This mini-review aims to summarize and discuss previous and recent advances in the clinical presentation, pathophysiology, diagnosis, treatment, and outcome of SARS-CoV-2-associated peripheral neuropathies. Methods: Literature review. Results: Altogether, 105 articles about SARS-CoV-2-associated neuropathy describing 261 patients were retrieved. Peripheral neuropathy in patients with COVID-19 is frequent and predominantly due to immune mechanisms or neurotoxic side effects of drugs used to treat the symptoms of COVID-19 and, to a lesser extent, due to the compression of peripheral nerves resulting from prolonged bedding in the Intensive Care Unit (ICU) and pre-existing risk factors such as diabetes. SARS-CoV-2 does not cause viral neuropathy. Neurotoxic drugs such as daptomycin, linezolid, lopinavir, ritonavir, hydro-chloroquine, cisatracurium, clindamycin, and glucocorticoids should be administered with caution and patients should be appropriately bedded in the ICU to prevent SARS-CoV-2-associated neuropathy. Patients with Guillain-Barré syndrome (GBS) benefit from immunoglobulins, plasma exchange, and steroids. Conclusions: Neuropathies of peripheral nerves in patients with COVID-19 are frequent and mostly result from immune mechanisms or neurotoxic side effects of drugs used to treat the symptoms of COVID-19 and, to a lesser extent, from the compression of peripheral nerves due to prolonged bedding on the ICU. SARS-CoV-2 does not cause infectious neuropathy.

show abstract

Section: Resultsmentioning

confidence: 99%

Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit

Finsterer

Scorza

et al. 2021

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Guillain-Barre syndrome (GBS) following a first or second dose of a SARS-CoV-2 vaccination has been previously reported [ [2] , [3] , [4] ]. It is also well-known that an infection with SARS-CoV-2 can be complicated by GBS [ 5 ]. However, GBS following a SARS-CoV-2 infection in a vaccinated patient has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Guillain-Barre syndrome 15 days after COVID-19 despite SARS-CoV-2 vaccination

Finsterer

2021

IDCases

Self Cite

View full text Add to dashboard Cite

Guillain-Barre syndrome (GBS) following a SARS-CoV-2 vaccination has been repeatedly observed but GBS following a SARS-CoV-2 infection in a vaccinated patient has not been reported. A 69yo female developed paresthesias of both lower and upper limbs which were followed by progressive muscle weakness. The history was positive for a mild SARS-CoV-2 infection 15 days earlier. COVID-19 occurred despite a first dose of a vector-based SARS-CoV-2 vaccine, 40 days prior to onset of GBS. Since CSF investigations and nerve conduction studies were indicative of GBS, subtype acute, inflammatory, demyelinating polyneuropathy (AIDP), immunoglobulins (30 g/d) were started. After two weeks complete recovery was achieved. In conclusion, SARS-CoV-2 infections may develop despite full vaccination and may be complicated by GBS. Since no other trigger of GBS could be identified, a causal relation between the SARS-CoV-2 infection and GBS was suspected.

show abstract

“…Missing is the subclassification of GBS. Though most of the cases of SARS-CoV-2 associated GBS were of the acute, inflammatory, demyelinating polyneuropathy (AIDP) type [ 3 ], several patients with acute, motor, axonal neuropathy (AMAN), acute, motor and sensory, axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS), and polyneuritis cranialis (PNC) have been reported [ 3 ]. Since treatment and response to it may vary between the various GBS subtypes, it is crucial to know if the GBS subtype was determined on follow-up NCSs.…”

mentioning

confidence: 99%

Guillain-Barre syndrome in 220 patients with COVID-19

Cited by 103 publications

References 11 publications

Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit

Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit

Guillain-Barre syndrome 15 days after COVID-19 despite SARS-CoV-2 vaccination

SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome

Contact Info

Product

Resources

About